Thibault Ronan, Welch Susan, Mauras Nelly, Sager Brenda, Altomare Astride, Haymond Morey, Darmaun Dominique
INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, Université de Nantes, 44093 Nantes cedex 1, France.
Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G548-53. doi: 10.1152/ajpgi.00461.2007. Epub 2007 Dec 27.
Glutamine is the most abundant amino acid in the body and is extensively taken up in gut and liver in healthy humans. To determine whether glucocorticosteroids alter splanchnic glutamine metabolism, the effect of prednisone was assessed in healthy volunteers using isotope tracer methods. Two groups of healthy adults received 5-h intravenous infusions of l-[1-(14)C]leucine and l-[(2)H(5)]glutamine, along with q. 20 min oral sips of tracer doses of l-[1-(13)C]glutamine in the fasting state, either 1) at baseline (control group; n = 6) or 2) after a 6-day course of 0.8 mg.kg(-1).day(-1) prednisone (prednisone group; n = 8). Leucine and glutamine appearance rates (Ra) were determined from plasma [1-(14)C]ketoisocaproate and [(2)H(5)]glutamine, respectively, and leucine and glutamine oxidation from breath (14)CO(2) and (13)CO(2), respectively. Splanchnic glutamine extraction was estimated by the fraction of orally administered [(13)C]glutamine that failed to appear into systemic blood. Prednisone treatment 1) did not affect leucine Ra or leucine oxidation; 2) increased plasma glutamine Ra, mostly owing to enhanced glutamine de novo synthesis (medians +/- interquartiles, 412 +/- 61 vs. 280 +/- 190 mumol.kg(-1).h(-1), P = 0.003); and 3) increased the fraction of orally administered glutamine undergoing extraction in the splanchnic territory (means +/- SE 64 +/- 6 vs. 42 +/- 12%, P < 0.05), without any change in the fraction of glutamine oxidized (means +/- SE, 75 +/- 4 vs. 77 +/- 4%, not significant). We conclude that high-dose glucocorticosteroids increase in splanchnic bed the glutamine requirements. The role of such changes in patients receiving chronic corticoid treatment for inflammatory diseases or suffering from severe illness remains to be determined.
谷氨酰胺是人体内最丰富的氨基酸,在健康人体内,肠道和肝脏会大量摄取谷氨酰胺。为了确定糖皮质激素是否会改变内脏谷氨酰胺代谢,研究人员使用同位素示踪法评估了泼尼松对健康志愿者的影响。两组健康成年人在空腹状态下接受5小时的静脉输注l-[1-(14)C]亮氨酸和l-[(2)H(5)]谷氨酰胺,同时每隔20分钟口服微量示踪剂量的l-[1-(13)C]谷氨酰胺,其中一组为1)基线时(对照组;n = 6),另一组为2)在接受6天、剂量为0.8 mg.kg(-1).day(-1)的泼尼松治疗后(泼尼松组;n = 8)。分别根据血浆中的[1-(14)C]酮异己酸和[(2)H(5)]谷氨酰胺测定亮氨酸和谷氨酰胺的出现率(Ra),并分别根据呼出气体中的(14)CO(2)和(13)CO(2)测定亮氨酸和谷氨酰胺的氧化率。内脏谷氨酰胺摄取量通过口服[(13)C]谷氨酰胺中未进入体循环血液的部分来估算。泼尼松治疗1)不影响亮氨酸的Ra或亮氨酸氧化;2)增加了血浆谷氨酰胺的Ra,主要是由于谷氨酰胺从头合成增强(中位数±四分位数间距,412±61对280±190 μmol.kg(-1).h(-1),P = 0.003);3)增加了在内脏区域摄取的口服谷氨酰胺的比例(平均值±标准误,64±6对42±12%,P < 0.05),而谷氨酰胺氧化比例没有任何变化(平均值±标准误,75±4对77±4%,无显著性差异)。我们得出结论,高剂量糖皮质激素会增加内脏对谷氨酰胺的需求。这种变化在接受慢性皮质类固醇治疗的炎症性疾病患者或重症患者中的作用仍有待确定。